Search results for "Etoposide"

showing 10 items of 97 documents

Blocking signaling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to eto…

1999

BACKGROUND The mechanisms of drug resistance associated with advanced, hormone-independent prostate carcinoma are poorly understood. The human prostate carcinoma PC-3 cell line, derived from a metastatic tumor and lacking androgen receptors, represents a useful model to investigate drug resistance. METHODS The effects of oncostatin M (OM), antiinterleukin-6 (IL-6) treatment, or interference with the gp130-mediated signaling on etoposide- or cisplatin-mediated cytotoxicity were investigated. RESULTS Both endogenous and exogenous IL-6 and exogenous OM up-regulated cell growth and enhanced resistance of PC-3 tumor cells to both etoposide and cisplatin. The influence of IL-6 is controlled by tr…

MaleCancer Researchmedicine.drug_classAntineoplastic AgentsOncostatin MBiologyCell surface receptorAntigens CDCyclohexenesmedicineCytokine Receptor gp130Tumor Cells CulturedHumansReceptorEtoposideEtoposideMembrane GlycoproteinsCell growthInterleukin-6TerpenesOncostatin MProstatic NeoplasmsGlycoprotein 130Receptor antagonistAntineoplastic Agents PhytogenicGenisteinOncologyDrug Resistance NeoplasmCancer researchbiology.proteinMonoterpenesSignal transductionCisplatinPeptidesmedicine.drugSignal Transduction
researchProduct

Malignant germ cell tumors in childhood: results of the first Italian cooperative study "TCG 91".

2003

Background and Aims About 20% of patients with germ cell tumor (GCT) are still resistant to therapy. To investigate which features are present in resistant patients, a multicenter study on GCT in children was undertaken to correlate clinical and laboratory parameters with the outcome. Methods Patients aged less than 16 years, with histologically proven extracranial GCT were included. Results Ninety-five patients (median age 33 months, 45 males) were eligible. The site of the primary tumor was gonadal in 59, extragonadal in 36. The stage was I in 39; II in 5; IIIa (microscopic residue) in 7; IIIb (macroscopic residue) in 16; IIIc (unresectable) in 13; IV in 15. The treatment was surgery alon…

MaleCancer Researchmedicine.medical_treatmentGastroenterologyCohort Studieschemistry.chemical_compoundChildmalignant germ cell tumorsEtoposideOvarian NeoplasmsIfosfamideIncidenceseminomaPrognosisCombined Modality TherapyPrimary tumorChemotherapy regimenTreatment OutcomeItalyOncologyChild PreschoolcarboplatinFemaleGerminomamedicine.drugmedicine.medical_specialtyAdolescentRisk Assessmentrisk factors in malignant germ cellAge Distributioncarboplatin; malignant germ cell tumors; risk factors in malignant germ cell; seminomaTesticular NeoplasmsInternal medicineConfidence IntervalsmedicineHumansSex DistributionSurvival analysisNeoplasm StagingProbabilityRetrospective StudiesChemotherapybusiness.industrySeminomamedicine.diseaseSurvival AnalysisCarboplatinSurgerychemistryMultivariate AnalysisPediatrics Perinatology and Child Healthbusiness
researchProduct

IL-4 protects tumor cells from anti-CD95 and chemotherapeutic agents via up-regulation of antiapoptotic proteins

2004

Abstract We recently proposed that Th1 and Th2 cytokines exert opposite effects on the pathogenesis and clinical outcome of organ-specific autoimmunity by altering the expression of genes involved in target cell survival. Because a Th2 response against tumors is associated with poor prognosis, we investigated the ability of IL-4 to protect tumor cells from death receptor- and chemotherapy-induced apoptosis. We found that IL-4 treatment significantly reduced CD95 (Fas/APO-1)- and chemotherapeutic drug-induced apoptosis in prostate, breast, and bladder tumor cell lines. Analysis of antiapoptotic protein expression revealed that IL-4 stimulation resulted in up-regulation of cellular (c) FLIP/F…

MaleINFILTRATING LYMPHOCYTESCell SurvivalImmunologyCASP8 and FADD-Like Apoptosis Regulating Proteinbcl-X ProteinAntineoplastic AgentsApoptosisBreast NeoplasmsCARCINOMA-CELLSBiologySIGNALING PATHWAYSDownregulation and upregulationCell Line TumorImmunology and AllergyHumansfas ReceptorNON-HODGKINS-LYMPHOMACANCER PATIENTSReceptorBCL-2 PROTEINInterleukin 4EtoposideIL-4 apoptosis cancer stem cellsSettore MED/04 - Patologia GeneraleCHRONIC LYMPHOCYTIC-LEUKEMIAIntracellular Signaling Peptides and ProteinsAntibodies MonoclonalProstatic NeoplasmsFas receptorRecombinant ProteinsCell biologyUp-RegulationProto-Oncogene Proteins c-bcl-2ApoptosisCell cultureFlipCancer researchT-CELLSCamptothecinFemaleInterleukin-4FLICE-INHIBITORY PROTEINSignal transductionCarrier ProteinsRENAL-CELL
researchProduct

A novel form of ataxia oculomotor apraxia characterized by oxidative stress and apoptosis resistance

2007

Several different autosomal recessive genetic disorders characterized by ataxia with oculomotor apraxia (AOA) have been identified with the unifying feature of defective DNA damage recognition and/or repair. We describe here the characterization of a novel form of AOA showing increased sensitivity to agents that cause single-strand breaks (SSBs) in DNA but having no gross defect in the repair of these breaks. Evidence for the presence of residual SSBs in DNA was provided by dramatically increased levels of poly (ADP-ribose)polymerase (PARP-1) auto-poly (ADP-ribosyl)ation, the detection of increased levels of reactive oxygen/nitrogen species (ROS/RNS) and oxidative damage to DNA in the patie…

MaleMethylnitronitrosoguanidineProgrammed cell deathAtaxiaDNA RepairApraxiasDNA damageMitomycinBlotting WesternPoly (ADP-Ribose) Polymerase-1Apoptosismedicine.disease_causeAntioxidantschemistry.chemical_compoundRadiation IonizingmedicineHumansDNA Breaks Single-StrandedOculomotor apraxiaMolecular BiologyCells CulturedEtoposideMembrane Potential MitochondrialbiologyCytochrome cHydrogen PeroxideCell BiologyFlow Cytometrymedicine.diseaseAntineoplastic Agents PhytogenicReactive Nitrogen SpeciesMolecular biologyOxidative StresschemistryApoptosisbiology.proteinAtaxiaCamptothecinFemalePoly(ADP-ribose) Polymerasesmedicine.symptomDNAOxidative stressDNA DamageCell Death & Differentiation
researchProduct

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of …

2006

Abstract Background Elderly patients have been often excluded from or underrepresented in the study populations of combination chemotherapy trials. The primary end point of this study was to determine the response rate and the toxicity of the weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) regimen in elderly patients with advanced gastric cancer. The secondary objective was to measure the time to disease progression and the survival time. Methods Chemotherapy-naive patients with advanced gastric cancer aged 70 or older were considered eligible for study entry. Patients received weekly oxaliplatin 40 mg/m2, fluorouracil 500 mg/m2 and folinic acid 250 mg/m2. All drugs were given i…

MaleOncologymedicine.medical_specialtyCancer ResearchOrganoplatinum Compoundsmedicine.medical_treatmentlcsh:RC254-282Drug Administration ScheduleLEUCOVORINFolinic acidEPI-DOXORUBICINTRACT CANCERCISPLATINADVANCED ESOPHAGOGASTRIC CANCERStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointGeneticsHumansAged6S-LEUCOVORINAged 80 and overCisplatinChemotherapybusiness.industryCombination chemotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensINFUSIONAL FLUOROURACILRANDOMIZED-TRIALOxaliplatinOxaliplatinSurvival RateRegimenOncologyFluorouracilINTENSIVE WEEKLY CHEMOTHERAPYETOPOSIDEFemaleFluorouracilbusinessResearch Articlemedicine.drug
researchProduct

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of …

2006

Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission. The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens. ASCT patients received Dexa-BEAM (Dexamethasone, BCNU, Melphalan, Etoposide, Cytarabine) for mobilization of stem cells. Stem cells were collected and a mini…

MaleOncologymedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellHematopoietic stem cell transplantationCHOPDexamethasone0302 clinical medicineAutologous stem-cell transplantationGermanyhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularMelphalanEtoposideCytarabineHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell Mobilization3. Good healthSurvival RateTreatment OutcomeOncologyVincristine030220 oncology & carcinogenesisFemalemedicine.drugAdultmedicine.medical_specialtyVincristinePrednisolone03 medical and health sciencesInternal medicinemedicineHumansCyclophosphamideAgedChemotherapyMitoxantronebusiness.industrymedicine.diseaseCarmustineLeukemia Lymphocytic Chronic B-CellSurgeryDoxorubicinPrednisoneChlorambucilMantle cell lymphomaMitoxantronebusiness030215 immunologyAnnals of Oncology
researchProduct

Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report.

2009

Abstract Background Transmission of donor-derived cancer by organ transplantation is rare, but the risk has been increasing due to the aging donor pool. Undifferentiated neuroendocrine small-cell carcinoma is an agressive tumor with the tendency to spread. Herein we have demonstrated different approaches to treat organ recipients with transmitted tumors. Methods and Results Grafts were retrieved from a decreased donor without any history of previous diseases. Autopsy was not performed after donation. The recipient of the liver graft presented with suspected nodules on routine abdominal ultrasound. After computed tomography (CT) scan, biopsy confirmed the diagnosis of a small-cell carcinoma.…

Malemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAutopsyAntineoplastic AgentsSmall-cell carcinomaNephrectomyOrgan transplantationCarboplatinalpha 1-Antitrypsin DeficiencyBiopsymedicineCarcinomaHumansCarcinoma Small CellNeoplasm MetastasisEtoposideTransplantationChemotherapymedicine.diagnostic_testbusiness.industryLiver NeoplasmsCancerMiddle Agedmedicine.diseaseDNA FingerprintingEmbolization TherapeuticKidney TransplantationTissue DonorsSurgeryLiver TransplantationTransplantationHeart TransplantationSurgerybusinessImmunosuppressive AgentsTransplantation proceedings
researchProduct

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

2007

Multisystem Langerhans cell histiocytosis (MS-LCH) is associated with high mortality when patients have risk organ involvement (RO+) or are younger than 2 years. In an international randomized trial, LCH-II, we intensified their treatment: arm A consisted of 6 weeks of daily prednisone and weekly vinblastine followed by 18 weeks of daily 6-mercaptopurine with vinblastine/prednisone pulses; etoposide was added in arm B. Considering all 193 randomized risk patients, there were similar outcomes: rapid (6 weeks) response (arm A vs arm B: 63%/71%), 5-year survival probability (74%/79%), disease reactivation frequency (46%/46%), and permanent consequences (43%/37%). However, (1) patients younger …

Malemedicine.medical_specialtyImmunologyAdult Langerhans Cell HistiocytosisBiochemistryGastroenterologylaw.inventionLangerhans cell histiocytosisRandomized controlled trialRisk FactorsPrednisonelawInternal medicineHumansMedicineEtoposideDemographyHematologybusiness.industryInfantCell BiologyHematologymedicine.diseaseSurgeryVinblastineSurvival RateHistiocytosis Langerhans-CellTreatment OutcomeChild PreschoolOrgan involvementFemalebusinessmedicine.drugBlood
researchProduct

A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly

2011

Alternative splicing of caspase-3 produces a short isoform caspase-3s that antagonizes caspase-3 apoptotic activity. However, the mechanism of apoptosis inhibition by caspase-3s remains unknown. Here we show that exogenous caspase-3 sensitizes MCF-7 and HBL100 breast cancers cells to chemotherapeutic treatments such as etoposide and methotrexate whereas co-transfection with caspase-3s strongly inhibits etoposide and methotrexate-induced apoptosis underlying thus the anti-apoptotic role of caspase-3s. In caspase-3 transfected cells, lamin-A and α-fodrin were cleaved when caspase-3 was activated by etoposide or methotrexate. When caspase-3s was co-transfected, this cleavage was strongly reduc…

Models MolecularImmunoprecipitationScienceBlotting WesternMolecular Sequence DataGene ExpressionApoptosisBreast NeoplasmsCaspase 3BiologyReal-Time Polymerase Chain ReactionBiochemistryRNA interferenceApoptosomesCell Line TumorMolecular Cell BiologyBreast CancermedicineHumansAmino Acid SequenceBiologyEtoposideDNA PrimersMultidisciplinaryCell DeathBase SequenceSequence Homology Amino AcidCaspase 3QRObstetrics and GynecologyTransfectionApoptosome assemblyMolecular biologyEnzymesEnzyme ActivationIsoenzymesApoptosisCancer researchMedicineApoptosomeResearch Articlemedicine.drugPLoS ONE
researchProduct

Nalidixic acid-resistant V79 cells with reduced DNA topoisomerase II activity and amplification prone phenotype

1992

Spontaneously nalidixic acid-resistant lines (NAr lines) were selected from a V79 Chinese hamster cell line and phenotypically characterized. NAr lines showed an increased doubling time, a higher number of spontaneous SCE, and more interestingly, decreased DNA topoisomerase II activity. These lines were also cross-resistant to the eukaryotic topoisomerase II inhibitors etoposide and adriamycin, but showed the same level of sensitivity as the parental line to the DNA topoisomerase I inhibitor camptothecin. NAr lines were cross-resistant to other drugs, such as PALA, MTX and MPA, resistance to which has been shown to arise by amplification of the target genes. This last feature, together with…

Nalidixic acidCell SurvivalHealth Toxicology and MutagenesisDrug ResistanceAntineoplastic AgentsBiologyCell LineNalidixic Acidchemistry.chemical_compoundCricetulusCricetinaeGeneticsmedicineAnimalsTopoisomerase II InhibitorsMolecular BiologyGeneEtoposideEtoposideCell NucleusMesocricetusTopoisomeraseGene AmplificationNucleic Acid HybridizationDNADNA topoisomerase II activityMolecular biologyDNA Topoisomerases Type IIPhenotypeDNA Topoisomerases Type IchemistryDoxorubicinbiology.proteinTopoisomerase-II InhibitorSister Chromatid ExchangeDNACamptothecinmedicine.drugMutation Research/Fundamental and Molecular Mechanisms of Mutagenesis
researchProduct